Table 1.
Baseline characteristics
| Female/male | 357/92 |
| Age years (mean ± SD, n = 449) | 84 ± 8 |
| BMI kg/m2 (mean ± SD, n = 444) | 24.0 ± 8.0 |
| Number of patients (%) | |
|---|---|
| Atherosclerotic co‐morbidity (n = 449) | |
| Coronary artery disease | 320 (71%) |
| Peripheral artery disease | 409 (91%) |
| History of stroke | 335 (75%) |
| Co‐medication (n = 449) | |
| Antidiabetic medicines | 337 (75%) |
| ACE‐inhibitors | 289 (64%) |
| Beta‐blockers | 378 (84%) |
| Calcium antagonists | 381 (85%) |
| Loop diuretics | 357 (79%) |
| Other diuretics | 426 (93%) |
| Proton pump inhibitors | 183 (41%) |
| Anticoagulation therapy | 163 (36%) |
| Selective serotonin re‐uptake inhibitors | 264 (59%) |
| Other antidepressants | 271 (60%) |
| Anxiolytic and hypnotic medicines | 308 (69%) |
| Neuroleptic medicine | 262 (58%) |
| HMG‐CoA‐Reduktase‐Inhibitor (n = 316) | 70 (22%) |
| Antiplatelet therapy (n = 316) | 166 (53%) |